Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASSION-01: Cadonilimab in advanced solid tumors
NCT03261011Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2017
- Primary completion
- Aug 2021
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadonilimab in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Dose Limiting Toxicity at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
cadonilimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03261011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261011.